Stonegate Updates AB Science Coverage
Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026
The updated stock coverage by Stonegate Capital Partners with a EUR 4.25 target price for AB Science could lead to increased investor interest and potentially a positive movement in AB Science's stock price. The detailed clinical progress in ALS and Acute myeloid leukemia, along with financing updates, provides a clearer picture for market participants, potentially de-risking the investment.
Stonegate Capital Partners has updated its coverage of AB Science's stock, setting a discounted cash flow valuation mid-point of EUR 4.25 per share. This update follows AB Science's full year 2025 results and highlights the company's strategic focus on masitinib for ALS and AB8939 for Acute myeloid leukemia. The confirmatory Phase 3 trial for masitinib in ALS is United States — Food and Drug Administration-authorized, and early data for AB8939 in Acute myeloid leukemia show promising responses. AB Science also secured a clinical trial financial insurance offer for AB23005 and improved its financial position with a private placement and reduced operating loss. This analysis by Stonegate Capital Partners contributes to the broader financial analyst consensus for AB Science.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard